Author:
Moreau Philippe,Karamanesht Ievgenii I.,Domnikova Natalia,Kyselyova Maryna Y.,Vilchevska Kateryna V.,Doronin Vadim A.,Schmidt Alexander,Hulin Cyrille,Leleu Xavier,Esseltine Dixie-Lee,Venkatakrishnan Karthik,Skee Donna,Feng Huaibao,Girgis Suzette,Cakana Andrew,van de Velde Helgi,Deraedt William,Facon Thierry
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference12 articles.
1. Janssen-Cilag International N.V. VELCADE® (bortezomib): summary of product characteristics. Beerse: Janssen-Cilag International N.V.; 2009.
2. Millennium Pharmaceuticals Inc. VELCADE® (bortezomib) for injection: prescribing information. Rev. 13. Cambridge: Millennium Pharmaceuticals Inc.; 2012.
3. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431–40.
4. Moreau P, Coiteux V, Hulin C, Leleu X, van de Velde H, Acharya M, et al. Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma. Haematologica. 2008;93:1908–11.
5. Greipp PR, San MJ, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献